

HeartBeam Granted Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

Patented Technology Allows HeartBeam AIMIGo™ Credit Card-sized Device to Enable a 12-lead ECG Anytime, Anywhere

SANTA CLARA, Calif.--(BUSINESS WIRE)-- **HeartBeam, Inc.** (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today that its patent that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo™ credit card-sized device was issued by the United States Patent and Trademark Office. The innovation opens the pathway for a patient to record a set of signals using HeartBeam AIMIGo outside of a medical setting with a diagnostic synthesized 12-lead ECG immediately transmitted to a physician for review and diagnosis. Unlike single-lead ECG products currently in the marketplace, such as other credit card sized devices or smartwatches, the HeartBeam technology is intended to quickly and accurately help a physician identify a heart attack (myocardial infarction).

In the US, approximately 18 million individuals have coronary artery disease putting them at an increased risk for a heart attack and making them ideal candidates for remote patient heart attack detection. In contrast, the market for atrial fibrillation, the most targeted condition for detection by single-lead ECG technologies, is several times smaller. A 12-lead ECG is the standard of care for detecting any cardiac condition and is considered one of the essential tools for heart attack detection. No single lead ECG product currently in the marketplace is able to help diagnose a heart attack. HeartBeam's technology will be the first and only 12-lead ECG solution that fits in a consumer's wallet for use anytime, anywhere.

"This patent provides additional intellectual property protection for our breakthrough AIMIGo technology offering 12-lead ECG capability in the form of a credit card-sized device with the same footprint as the single-lead products currently in the market today," said HeartBeam CEO and Founder Branislav Vajdic, PhD. "Our 12-lead AIMIGo technology, which is part of our granted patent, offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care. This could reduce the critical time to intervention for heart attack patients, saving lives and reducing healthcare costs by ruling out a heart attack and reducing the number of emergency room visits."

The newly issued patent (No. 11,445,963 B2) expands on HeartBeam's granted and pending core patents for remote heart attack detection. The value of the recently granted 12-lead ECG patch patent is in addressing the market need for multi-week, continuous monitoring while the AIMIGo solution is always with the patient, providing a means for timely heart attack intervention. This may increase quality of life for cardiac patients by reducing the fear

of chest pain and provide added peace of mind. At the core of both products is HeartBeam's breakthrough ability to provide a patient-friendly means of obtaining a 12-lead ECG anytime, anywhere.

"The availability of a remote 12-lead ECG transmitted to a physician while the patient is symptomatic and outside of a medical facility allows a standard of care level of diagnostic work in any setting and may potentially accelerate pre-hospital care," said C. Michael Gibson, MD, MS, CEO of the non-profit Baim and PERFUSE research institutes at Harvard Medical School, also a leading digital influencer, and Chairman of HeartBeam's Scientific Advisory Board. "A 12-lead symptomatic signal combined with a 12-lead baseline signal would provide additional information to aid in diagnosing conditions such as myocardial infarction or more complex arrhythmias that current single-lead remote cardiac technologies cannot accurately detect."

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI™ is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMiGo™ is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMiGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies. For more information, visit [HeartBeam.com](https://www.heartbeam.com).

Forward-Looking Statements

All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our in our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20220928005074/en/>

Investor Relations Contact:

Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us

Media Contact:

Capwell Communications
media@capwellcomm.com
949-999-3303

Source: HeartBeam, Inc.